STELAZINE
LOE ApproachingNDAINJECTIONINJECTABLE
Approved
Apr 1959
Lifecycle
LOE Approaching
Competitive Pressure
30/100
Data completeness
1/8 — Limited
Drug data last refreshed 22h ago · AI intelligence enriched 3w ago
AI summarySynthesized from FDA + DailyMed + ClinicalTrials.gov data
STELAZINE is a legacy injectable antipsychotic approved in 1959 for psychiatric disorders. The drug's exact mechanism and indications are not documented in available records, but as a small-molecule injection it likely targets dopamine pathways. It represents an older generation of neuroleptic therapy now superseded by newer atypical antipsychotics.
LOE Approaching
Legacy product approaching loss of exclusivity with minimal linked opportunities; team size likely small and focused on compliance and managed decline.
Mechanism of Action
Mechanism of action data is being enriched from DailyMed and FDA sources. Check back soon for updated drug intelligence.
Indications
Indication data is being enriched from DailyMed and FDA labeling. Check back soon for approved therapeutic uses.
Career Relevance
Working on STELAZINE offers limited career advancement due to its legacy status and minimal commercial momentum. Roles are maintenance-oriented with emphasis on compliance, formulary access, and managed stakeholder relationships in institutional psychiatry.
Brand ManagerRegulatory Affairs Specialist
Worked on STELAZINE at GSK? Share your interview experience or compensation data (+7 days Pro)
Data Sources
- Drug label: DailyMed / FDA
- Clinical trials: ClinicalTrials.gov
- Patent data: FDA Orange Book
- Spending data: CMS Medicare
The information on this page is for informational purposes only and should not be used as a substitute for professional medical advice. Drug information is sourced from FDA, DailyMed, and other government databases. Adverse event data from FAERS does not establish causation. Always consult a healthcare professional for medical decisions.